Cargando…

Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation

Despite intensive research no therapies targeted against the oncogenic EGFRvIII are present in the clinic. One of the reasons is the elusive nature of the molecular structure and activity of the truncated receptor. The recent publications indicate the EGF-bound wild-type EGFR to trans-phosphorylate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stec, Wojciech, Rosiak, Kamila, Treda, Cezary, Smolarz, Maciej, Peciak, Joanna, Pacholczyk, Marcin, Lenart, Anna, Grzela, Dawid, Stoczynska-Fidelus, Ewelina, Rieske, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823601/ https://www.ncbi.nlm.nih.gov/pubmed/29492217 http://dx.doi.org/10.18632/oncotarget.24058

Ejemplares similares

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy
por: Tręda, Cezary, et al.
Publicado: (2023)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Efficient and simple approach to in vitro culture of primary epithelial cancer cells
por: Janik, Karolina, et al.
Publicado: (2016)

IDH1(R132H) in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis
por: Rosiak, Kamila, et al.
Publicado: (2016)

Low Incidence along with Low mRNA Levels of EGFR(vIII) in Prostate and Colorectal Cancers Compared to Glioblastoma
por: Peciak, Joanna, et al.
Publicado: (2017)

EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line
por: Treda, Cezary, et al.
Publicado: (2016)

Cell line with endogenous EGFR(vIII) expression is a suitable model for research and drug development purposes
por: Stec, Wojciech J., et al.
Publicado: (2016)

A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells – possible approaches to circumvent these phenomena
por: Janik, Karolina, et al.
Publicado: (2019)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors
por: Walczak, Maciej P., et al.
Publicado: (2016)

Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system
por: Drozd, Anna M., et al.
Publicado: (2015)

SOX2 and SOX2-MYC Reprogramming Process of Fibroblasts to the Neural Stem Cells Compromised by Senescence
por: Winiecka-Klimek, Marta, et al.
Publicado: (2015)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018)

Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line
por: STOCZYNSKA-FIDELUS, EWELINA, et al.
Publicado: (2016)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

Gaps and Doubts in Search to Recognize Glioblastoma Cellular Origin and Tumor Initiating Cells
por: Wlodarczyk, Aneta, et al.
Publicado: (2020)

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
por: Wheeler, Sarah E., et al.
Publicado: (2015)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

PIN3 duplication may be partially responsible for TP53 haploinsufficiency
por: Winiecka-Klimek, Marta, et al.
Publicado: (2014)

The Failure in the Stabilization of Glioblastoma-Derived Cell Lines: Spontaneous In Vitro Senescence as the Main Culprit
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2014)

Different mutational characteristics of TSG in cell lines and surgical specimens
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2014)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

EGFR(vIII): An Oncogene with Ambiguous Role
por: Rutkowska, Adrianna, et al.
Publicado: (2019)

Role of Senescence in Tumorigenesis and Anticancer Therapy
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2022)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis
por: Luo, Chang-Liang, et al.
Publicado: (2018)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
por: Ellwanger, Kristina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1l1v2kqqvcvh4grsnrcnqkv40a